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Manuscript (Revised)
Background  
 
Optimising the use of antimicrobials is a key priority of the global strategy to combat antimicrobial 
resistance (AMR).1 Antibiotic guidance should be developed to meet the aims of Sustainable 
Development Goal 3 - achieving universal access to safe, effective, quality and affordable 
medicines.2 Improving global prescribing is a complex issue which requires pragmatic short-term 
targets, ambitious long-term goals and realistic expectations. In low and middle-income countries 
(LMIC) settings, there are difficulties in identifying specific targets for intervention.3 Furthermore, 
sustained, reliable availability of antibiotics at an affordable cost and adequate quality remains a 
major concern for both high-income countries (HICs) and LMICs.4 Regular shortages and high cost of 
older off patent antibiotics are an increasing threat to their optimal use.5 Defining which antibiotics 
should be the focus of different levels of stewardship intervention is a global priority.6 
 
Revision of the Essential Medicines List (EML) also entails complex decisions assessing health 
outcomes while accounting for feasibility, monitoring, registration, and cost of listed medications.7 
The last complete revision of antibiotics was conducted in 2001.8 For the 2017 EML update, 
comprehensive reviews on antibiotic use for specific clinical infections were commissioned by the 
WHO.9 After assessing the evidence on the most frequent and severe bacterial infections, the Expert 
Committee has identified a limited number of options as first and second choice antibiotics for each 
of them and finally categorised antibiotics into three groups with the goal of improving access and 
clinical outcomes, reduce the potential for development of AMR and preserve the effectiveness of 
‘last resort’ antibiotics (Figure).  
 
New WHO EML/EMLc Antibiotic Groups – Access, Watch, Reserve – AWaRe 
 
Access Group 
 
To improve access to effective therapy, the Committee designated specific ‘Access’ antibiotics. 
Antibiotics selected for the Access group were those listed as first and second choice for the empiric 
treatment of 21 common or severe clinical syndromes. First choices were generally narrow spectrum 
agents with a lower toxicity risk. Second choices for specific syndromes were broader spectrum 
antibiotics that may have an increased risk of toxicity or resistance selection. This access designation 
for 29 antibiotics emphasises their role as the core set of antibiotics that should be consistently 
available everywhere at an appropriate quality, dose, duration, formulation and price. 
 
Watch Group 
 
The Watch group includes antibiotic classes that were considered generally to have higher toxicity 
concerns or resistance potential. This group is also substantially overlapping with the highest priority 
agents on the list of Critically Important Antimicrobials (CIA) for Human Medicine.10 That means the 
antibiotics that should not be used for prophylactic uses in  food producing animals and agriculture. 
A small number of antibiotics from the Watch group were also recommended as first or second 
choice treatments only for a limited number of specific indications. Antibiotics were designated to 
the Watch group to assist the development of tools for stewardship at local, national, and global 
levels. Active monitoring of the Watch antibiotics is encouraged through point-prevalence surveys to 
ensure use aligns with guidance.  
 
Reserve Group 
 
The Reserve group includes antibiotics which should be treated as ‘last-resort’ options. These should 
be accessible when needed, but use should be tailored to highly specific patients and clinical 
settings, when other alternatives have failed or cannot be used (e.g., serious or life-threatening 
infections due to multi-drug resistant bacteria). These medicines should be protected and prioritized 
as key targets of high-intensity national and international stewardship programs involving central 
monitoring and reporting, to preserve their effectiveness. The Reserve group also includes newer 
antibiotics.  
 
Scope and Limitations  
 
Several major limitations to this type of new broad categorisation remain. Not all classes of 
antibiotics are included in the list. There is a weak evidence base for recommending specific 
antibiotics or classes into the different categories though the relation between use of specific classes 
and propensity for resistance selection seemed sufficient to recommend this categorisation to 
facilitate stewardship. It is recognised that the List will need local adaptation and further revision 
over time.  
 
Future Directions  
 
A standing EML Working Group has been established to review additional syndromes, adapt current 
synopsis into short structured documents, coordinate the development of a guidance document on 
optimal dose and duration of antibiotic treatments and to improve methods for communicating the 
stewardship messages associated with these new Access, Watch, and Reserve (AWaRe) groups.  
An AWaRe Index, a novel metric for stewardship, could be introduced, to help estimate the relative 
use of narrow and broad spectrum antibiotics. This could enable relevant stakeholders to track 
progress in optimising use, evaluate impact of interventions and define ambitions for quality 
improvement. WHO member states would need to be supported as the clinical guidance is 
contextualised and implemented in their settings.  
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Figure 1 Classification of antibiotics into AWaRe groups: Access (green), Watch (yellow), and Reserve (red) 
   
ACCESS 
   
 amoxicillin 
amoxicillin + clavulanic acid 
ampicillin 
benzathine benzylpenicillin 
benzylpenicillin 
cefalexin / cefazolin 
chloramphenicol 
clindamycin 
cloxacillin 
doxycyline 
gentamicin / amikacin 
metronidazole 
nitrofurantoin 
phenoxymethylpenicillin  
procaine benzylpenicillin 
spectinomycin 
sulfamethoxazole + trimethoprim 
 
 
Core Access antibiotics 
azithromycin* 
cefixime* 
cefotaxime* 
ceftriaxone* 
ciprofloxacin* 
clarithromycin* 
piperacillin + tazobactam* 
meropenem* 
vancomycin* 
 
 
 
* denotes antibiotics which are also in the 
Watch group 
 
   
   
WATCH 
   
 
Anti-pseudomonal penicillins with beta-lactamase inhibitor (e.g. piperacillin + tazobactam) 
Carbapenems / Penems (e.g. faropenem, imipenem + cilastatin, meropenem) 
Cephalosporins, 3rd Generation (with or without beta-lactamase inhibitor, e.g. cefixime, 
cefotaxime, ceftazidime, ceftriaxone) 
Glycopeptides (e.g. teicoplanin, vancomycin) 
Macrolides (e.g. azithromycin, clarithromycin, erythromycin) 
Quinolones and fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin) 
 
   
   
RESERVE 
   
 
Aztreonam 
Cephalosporins, 4th Generation (e.g. cefepime) 
Cephalosporins, 5th Generation (e.g. ceftaroline) 
Daptomycin 
Fosfomycin (IV) 
Oxazolidinones (e.g. linezolid) 
Polymyxins (e.g. colistin, polymyxin B) 
Tigecycline 
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